Omega-3 polyunsaturated fatty acids for the management of metabolic syndrome in psychotic disorders: A systematic review and meta-analysis
Rainford A, Connor J, Lochtenberg J, Hallahan B
Schizophrenia research · 0 citas
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Organización sin fines de lucro
- Royal College of Surgeons in Ireland
Según 1 financiador declarado.
Publicación
- Publicado
- 2026-05-26 · Schizophr Res · vol. 295 · págs. 101–109
- Editorial
- Elsevier BV
- Citado
- 0 citas · más que el 29% de estudios similares · 0.0× el promedio de su campo
- Referencias
- 32 trabajos
- Acceso
- De pago
- Áreas de investigación
- Fatty Acid Research and Health · Schizophrenia research and treatment · Aquaculture Nutrition and Growth
- Palabras clave
- omega-3 polyunsaturated fatty acids, metabolic syndrome
- MeSH
- humans, fatty acids, omega-3, psychotic disorders, metabolic syndrome
4 autores
- A. Rainford🇮🇪 · autor de correspondenciaRoyal College of Surgeons in Ireland; Beaumont Hospital
- J. Connor🇮🇪Royal College of Surgeons in Ireland; Beaumont Hospital
- Jessica Lochtenberg🇦🇺St Vincent's Hospital Sydney
- Brian P. Hallahan🇮🇪Ollscoil na Gaillimhe – University of Galway
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Individuals with psychotic disorders, particularly schizophrenia, experience significantly elevated rates of metabolic syndrome, often linked to antipsychotic treatment. Omega-3 polyunsaturated fatty acids (PUFAs) have demonstrated cardiovascular and mood benefits, but their effects on metabolic outcomes in psychotic disorders remain unclear, with no prior systematic review dedicated to this population.
Methods
A systematic bibliographic search of randomised controlled trials and comparative studies assessing the effect of omega-3 PUFAs on metabolic outcomes in individuals with psychotic disorders was conducted. Outcomes included body mass index (BMI), waist circumference, serum triglycerides, low- and high-density lipoproteins, total cholesterol, blood glucose, and blood pressure. Seven randomised placebo-controlled trials were included in meta-analyses, with four additional open-label or non-randomised trials reviewed narratively.
Results
Omega-3 PUFAs demonstrated no statistically significant effect on several metabolic parameters including BMI, waist circumference, serum glucose, lipid profiles, or blood pressure. Heterogeneity was moderate to high across outcomes (I2 range of 31-99%), reflecting variability in study design, treatment duration, and populations. Isolated benefits were observed in first-episode psychosis, but these were not significant in pooled analyses.
Conclusions
Current evidence does not support a consistent metabolic benefit of omega-3 PUFA supplementation in psychotic disorders. Given methodological variability across studies and promising subgroup findings, further large-scale, standardised RCTs with metabolic outcomes as primary endpoints are warranted. While the heterogeneity of results limits interpretability, at present, omega-3 PUFAs cannot be recommended as a metabolic risk-reduction strategy in psychosis.
Prospero registration
CRD420251067935.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.